Home/Pipeline/Tyemvers (CKDB-501)

Tyemvers (CKDB-501)

Major Depressive Disorder (MDD)

Pre-clinicalActive

Key Facts

Indication

Major Depressive Disorder (MDD)

Phase

Pre-clinical

Status

Active

Company

Healis Therapeutics

About Healis Therapeutics

Healis Therapeutics is an emerging biotech company developing a novel therapeutic approach for neuropsychiatric conditions using targeted neuromodulation via botulinum toxin. The company's lead program, Tyemvers (CKDB-501), is being developed for Major Depressive Disorder (MDD) and is supported by a supply agreement with CKD Bio and a research collaboration with Massachusetts General Hospital. Healis is building a compelling scientific rationale based on published clinical evidence and is positioning itself to address significant unmet needs in treatment-resistant psychiatry.

View full company profile

Therapeutic Areas

Psychiatry Neurology

Other Major Depressive Disorder (MDD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
Deep TMS (H1 Coil)	BrainsWay	FDA Cleared	Commercial
EXXUA™ (gepirone ER)	Aytu BioPharma	Commercial	Launched
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
INV-202 (Oral & LAI)	Indivior	Preclinical	Discovery
NeuroStar Advanced Therapy	Neuronetics	FDA Cleared	Commercial
Gepirone ER	Fabre-Kramer Pharmaceuticals	NDA Submitted	Active
Exablate Neuro	Insightec	Clinical Trial	Active
BrightKaire Platform for Depression	NeuroKaire	Pre-clinical	Active
VENTURA-7	New Hope Clinical Research	Phase 2/3	Active
DT-101	Draig Therapeutics	Phase 2	Active
Major Depressive Disorder Program	Actipulse Neuroscience	Phase 3	Active